ArticleCureus2026
Sequential Immune-Mediated Extrahepatic Complications of Hepatitis E Virus: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis E virus (HEV) infection is classically described as causing self-limiting acute hepatitis. However, it is increasingly being recognised for a wide spectrum of immune-mediated extrahepatic complications involving the haematological, neurological, renal and pancreatic systems. These manifestations are more commonly seen as isolated presentations in individual patients. We report a 59-year-old man with serologically confirmed acute hepatitis E, in whom alternative infectious, autoimmune, and malignant etiologies were excluded, who developed three distinct immune-mediated complications in temporal sequence during a single hospital admission: autoimmune haemolytic anaemia (AIHA) at presentation, secondary haemophagocytic lymphohistiocytosis (HLH) within one week, and Guillain-Barré syndrome (GBS) on day 17. The chronological evolution of these complications suggested a progressive triphasic immune-mediated response following acute HEV infection. Each complication was diagnosed using established criteria and managed with targeted therapy-corticosteroids and supportive care for AIHA; etoposide, escalated dexamethasone, and cyclosporin for HLH; and intravenous immunoglobulin for GBS. The sequential development from early autoantibody-mediated haemolysis to hyperinflammatory macrophage activation and subsequent delayed post-infectious neuroimmune involvement reflects evolving immune dysregulation rather than coincident multisystem disease. The patient achieved complete clinical and biochemical recovery on follow-up. Sequential occurrence of AIHA, HLH, and GBS following acute HEV infection within a single hospital admission is rarely described. The case underscores the importance of maintaining a high index of suspicion for evolving extrahepatic immune-mediated complications in patients with acute HEV infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.